MASH resolution without worsening of fibrosis
Primary histological endpoint used in the MAESTRO-NASH and ESSENCE trials, assessed by biopsy. It is an intermediate or surrogate endpoint: it has not yet been shown to translate into fewer deaths, transplants or cases of liver cancer.
Institutional endorsement by Clínica Evolution
This entry is for information. Your case requires an individual medical assessment.